Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Dobutamine | hsa00030 | Pentose phosphate pathway | 3.13E-06 | 5 | P60891, P51854, P52209, P11413, P37837 | PRPS1, TKTL1, PGD, G6PD, TALDO1 | More | | Dobutamine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Dobutamine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Dobutamine | hsa00310 | Lysine degradation | 4.57E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | Dobutamine | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | | Dobutamine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Dobutamine | hsa00562 | Inositol phosphate metabolism | 2.00E-02 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | Dobutamine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Dobutamine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.15E-03 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | | Dobutamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Dobutamine | hsa00920 | Sulfur metabolism | 3.18E-02 | 1 | Q16762 | TST | More | | Dobutamine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | Dobutamine | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Dobutamine | hsa01200 | Carbon metabolism | 2.23E-02 | 4 | P51854, P11413, P37837, P60891 | TKTL1, G6PD, TALDO1, PRPS1 | More | | Dobutamine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Dobutamine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Dobutamine | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Dobutamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Dobutamine | hsa03040 | Spliceosome | 5.76E-08 | 17 | Q14562, O43143, O60508, P17844, P08579, P26368, P51991, P61978, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, DDX5, SNRPB2, U2AF2, HNRPA3, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | 0.888 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | 0.953 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O60508 | CDC40 | Pre-mRNA-processing factor 17 | 0.838 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P17844 | DDX5 | Probable ATP-dependent RNA helicase DDX5 | 0.73 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | 0.788 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P51991 | HNRPA3 | Heterogeneous nuclear ribonucleoprotein A3 | 0.787 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P61978 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 0.827 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | 0.935 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | 0.882 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | 0.886 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.746 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.709 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
| Dobutamine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Dobutamine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04012 | ErbB signaling pathway | 2.00E-02 | 4 | P16333, P17252, P19174, P42338 | NCK1, PRKCA, PLCG1, PIK3CB | More | | Dobutamine | hsa04014 | Ras signaling pathway | 5.57E-05 | 13 | P42338, P20827, P49767, P08069, Q13009, P17252, P14921, Q7LDG7, P0DP23, P62873, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, PRKCA, ETS1, RASGRP2, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Dobutamine | hsa04015 | Rap1 signaling pathway | 3.30E-05 | 14 | P20827, P49767, P08069, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P0DP23, P08514, P17252, P19174 | EFNA1, VEGFC, IGF1R, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, CALM1, ITGA2B, PRKCA, PLCG1 | More | | Dobutamine | hsa04020 | Calcium signaling pathway | 4.34E-02 | 6 | P27987, P17252, O15399, P19174, P0DP23, P49767 | ITPKB, PRKCA, GRIN2D, PLCG1, CALM1, VEGFC | More | | Dobutamine | hsa04024 | cAMP signaling pathway | 4.34E-02 | 6 | P42338, P0DP23, Q13370, O15399, P25963, Q13009 | PIK3CB, CALM1, PDE3B, GRIN2D, NFKBIA, TIAM1 | More | | Dobutamine | hsa04062 | Chemokine signaling pathway | 4.05E-04 | 14 | P09769, P07948, P42338, P19174, P62873, P63218, P50151, P43250, Q7LDG7, Q13009, P14598, P42224, P25963, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, NCF1, STAT1, NFKBIA, PIK3R5 | More | | Dobutamine | hsa04064 | NF-kappa B signaling pathway | 1.60E-02 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | | Dobutamine | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04070 | Phosphatidylinositol signaling system | 3.29E-03 | 6 | P19174, P0DP23, P42338, P23743, P27987, P17252 | PLCG1, CALM1, PIK3CB, DGKA, ITPKB, PRKCA | More | | Dobutamine | hsa04071 | Sphingolipid signaling pathway | 7.02E-07 | 8 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | | Dobutamine | hsa04080 | Neuroactive ligand-receptor interaction | 2.16E-03 | 9 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, C3AR1, ADRB2 | More | | Dobutamine | hsa04114 | Oocyte meiosis | 3.19E-03 | 5 | P51812, Q02750, P16298, Q17RY0, P08069 | RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | | Dobutamine | hsa04115 | p53 signaling pathway | 3.98E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Dobutamine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Dobutamine | hsa04122 | Sulfur relay system | 3.18E-02 | 1 | Q16762 | TST | More | | Dobutamine | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04141 | Protein processing in endoplasmic reticulum | 1.91E-03 | 6 | P18848, Q15437, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, HSPA8, HSP90AA1, SAR1A | More | | Dobutamine | hsa04145 | Phagosome | 1.81E-02 | 7 | O75015, Q15080, Q13488, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Dobutamine | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | | Dobutamine | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P08069, Q02750, Q9NQL2, P51812 | IGF1R, MAP2K1, RRAGD, RPS6KA3 | More | | Dobutamine | hsa04151 | PI3K-Akt signaling pathway | 7.36E-05 | 23 | P62753, P42338, P43657, P27348, P20827, P49767, P07900, P08238, Q8WYR1, P62873, P63218, P50151, P16144, O15335, Q13751, P22105, P14784, P01568, Q99941, P18848, P17252, O00141, P30281 | RPS6, PIK3CB, P2RY5, YWHAQ, EFNA1, VEGFC, HSP90AA1, HSP90AB1, PIK3R5, GNB1, GNG5, GNG10, ITGB4, CHAD, LAMB3, TNXB, IL2RB, IFNA21, CREBL1, ATF4, PRKCA, SGK, CCND3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P62753 | RPS6 | 40S ribosomal protein S6 | 0.722 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P27348 | YWHAQ | 14-3-3 protein theta | 0.833 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P20827 | EFNA1 | Ephrin-A1 | -0.872 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P20827 | EFNA1 | Ephrin-A1 | 0.715 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.871 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | 1 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P16144 | ITGB4 | Integrin beta-4 | -0.705 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O15335 | CHAD | Chondroadherin | -0.719 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O15335 | CHAD | Chondroadherin | 0.795 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.705 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P22105 | TNXB | Tenascin-X | 0.777 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | Q99941 | CREBL1 | Cyclic AMP-dependent transcription factor ATF-6 beta | 0.777 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P18848 | ATF4 | Cyclic AMP-dependent transcription factor ATF-4 | 0.783 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | O00141 | SGK | Serine/threonine-protein kinase Sgk1 | 0.709 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 |
| Dobutamine | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04210 | Apoptosis | 3.77E-02 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, P18848, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ATF4, ITPR1 | More | | Dobutamine | hsa04211 | Longevity regulating pathway | 5.33E-03 | 4 | P08069, P51828, Q99941, P18848 | IGF1R, ADCY7, CREBL1, ATF4 | More | | Dobutamine | hsa04213 | Longevity regulating pathway - multiple species | 2.83E-03 | 3 | P08069, Q9Y4H2, Q13547 | IGF1R, IRS2, HDAC1 | More | | Dobutamine | hsa04217 | Necroptosis | 2.97E-03 | 11 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, P15104, Q6FI13, Q99878, O43633 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, GLUL, H2AC18; H2AC19, H2AC14, CHMP2A | More | | Dobutamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.33E-03 | 7 | P07550, P51828, P22694, Q99941, P18848, Q13362, Q13557 | ADRB2, ADCY7, PRKACB, CREBL1, ATF4, PPP2R5C, CAMK2D | More | | Dobutamine | hsa04360 | Axon guidance | 5.10E-04 | 8 | P16333, P20827, O95631, P17252, P42338, P07332, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, FES, CFL1, PLCG1 | More | | Dobutamine | hsa04370 | VEGF signaling pathway | 1.04E-04 | 6 | P19174, P16298, P42338, P17252, Q05397, Q02750 | PLCG1, PPP3CB, PIK3CB, PRKCA, PTK2, MAP2K1 | More | | Dobutamine | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Dobutamine | hsa04510 | Focal adhesion | 2.69E-03 | 10 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P08069, P49767 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, IGF1R, VEGFC | More | | Dobutamine | hsa04512 | ECM-receptor interaction | 3.73E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Dobutamine | hsa04514 | Cell adhesion molecules | 8.19E-03 | 3 | P16109, P56750, O00501 | SELP, CLDN17, CLDN5 | More | | Dobutamine | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04530 | Tight junction | 1.38E-04 | 5 | Q8TEU7, P16989, P56750, O00501, Q14247 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN | More | | Dobutamine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04610 | Complement and coagulation cascades | 1.03E-03 | 3 | P25116, P09871, P0C0L4 | F2R, C1S, C4A | More | | Dobutamine | hsa04611 | Platelet activation | 5.18E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Dobutamine | hsa04612 | Antigen processing and presentation | 2.09E-04 | 8 | P13765, P48382, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Dobutamine | hsa04613 | Neutrophil extracellular trap formation | 2.31E-07 | 25 | P17252, P16109, P11215, O60603, P05164, P08246, Q9UM07, Q13547, P04908, Q6FI13, Q93077, P58876, Q16778, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P08514, P21462, P07359, O43315, Q16539 | PRKCA, SELP, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, ITGA2B, FPR1, GP1BA, AQP9, MAPK14 | More | | Dobutamine | hsa04623 | Cytosolic DNA-sensing pathway | 4.57E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Dobutamine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.52E-05 | 10 | P16298, P50591, P01375, P20963, Q02750, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | | Dobutamine | hsa04657 | IL-17 signaling pathway | 4.27E-03 | 7 | O00463, Q16539, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | | Dobutamine | hsa04659 | Th17 cell differentiation | 2.10E-03 | 10 | P25963, P19174, P42224, P14784, P14778, P40189, P84022, Q13485, P08238, P07766 | NFKBIA, PLCG1, STAT1, IL2RB, IL1R1, IL6ST, SMAD3, SMAD4, HSP90AB1, CD3E | More | | Dobutamine | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Dobutamine | hsa04664 | Fc epsilon RI signaling pathway | 1.23E-04 | 6 | P42338, P17252, P07948, P19174, P09917, P20292 | PIK3CB, PRKCA, LYN, PLCG1, ALOX5, ALOX5AP | More | | Dobutamine | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | Dobutamine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Dobutamine | hsa04713 | Circadian entrainment | 1.24E-02 | 5 | O15399, P0DP23, P17252, P62873, P50151 | GRIN2D, CALM1, PRKCA, GNB1, GNG10 | More | | Dobutamine | hsa04714 | Thermogenesis | 6.01E-04 | 8 | Q16539, P51828, P62753, P33121, P12074, O15239, Q16718, O14521 | MAPK14, ADCY7, RPS6, ACSL1, COX6A1, NDUFA1, NDUFA5, SDHD | More | | Dobutamine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Dobutamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Dobutamine | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Dobutamine | hsa04724 | Glutamatergic synapse | 8.08E-03 | 5 | O15399, P17252, P62873, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG10, GLUL | More | | Dobutamine | hsa04725 | Cholinergic synapse | 5.91E-04 | 10 | P51828, P22694, Q14643, P17252, P62873, P50151, P18848, Q13557, P42338, P10415 | ADCY7, PRKACB, ITPR1, PRKCA, GNB1, GNG10, ATF4, CAMK2D, PIK3CB, BCL2 | More | | Dobutamine | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | Dobutamine | hsa04727 | GABAergic synapse | 1.23E-02 | 4 | P62873, P50151, P15104, P17252 | GNB1, GNG10, GLUL, PRKCA | More | | Dobutamine | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Dobutamine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | Dobutamine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Dobutamine | hsa04744 | Phototransduction | 1.67E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Dobutamine | hsa04810 | Regulation of actin cytoskeleton | 2.58E-02 | 3 | Q15746, P08514, P25116 | MYLK, ITGA2B, F2R | More | | Dobutamine | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Dobutamine | hsa04912 | GnRH signaling pathway | 6.52E-04 | 8 | P17252, P51828, P18848, Q13557, Q16539, Q9Y6R4, Q14643, P22694 | PRKCA, ADCY7, ATF4, CAMK2D, MAPK14, MAP3K4, ITPR1, PRKACB | More | | Dobutamine | hsa04913 | Ovarian steroidogenesis | 7.72E-03 | 3 | P42330, P22694, P08069 | AKR1C3, PRKACB, IGF1R | More | | Dobutamine | hsa04914 | Progesterone-mediated oocyte maturation | 7.03E-04 | 9 | P08069, Q17RY0, P42338, Q13370, Q9UJX4, P30304, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, ANAPC5, CDC25A, HSP90AB1, RPS6KA3, MAP2K1 | More | | Dobutamine | hsa04915 | Estrogen signaling pathway | 9.55E-04 | 9 | P14780, P22694, Q99941, P18848, P51828, P07900, P11142, Q14643, P10415 | MMP9, PRKACB, CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8, ITPR1, BCL2 | More | | Dobutamine | hsa04918 | Thyroid hormone synthesis | 6.10E-04 | 6 | P22694, P51828, Q99941, P18848, Q14643, P02768 | PRKACB, ADCY7, CREBL1, ATF4, ITPR1, ALB | More | | Dobutamine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Dobutamine | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Dobutamine | hsa04926 | Relaxin signaling pathway | 1.15E-04 | 12 | P25963, P42338, P62873, P50151, Q99941, P18848, P22694, P49767, P14780, P51828, P17252, P30679 | NFKBIA, PIK3CB, GNB1, GNG10, CREBL1, ATF4, PRKACB, VEGFC, MMP9, ADCY7, PRKCA, GNA15 | More | | Dobutamine | hsa04927 | Cortisol synthesis and secretion | 1.11E-05 | 5 | Q14643, Q99941, P18848, P51828, P22694 | ITPR1, CREBL1, ATF4, ADCY7, PRKACB | More | | Dobutamine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.22E-04 | 8 | Q14643, P51828, P22694, P23771, P17252, Q99941, P18848, P10415 | ITPR1, ADCY7, PRKACB, GATA3, PRKCA, CREBL1, ATF4, BCL2 | More | | Dobutamine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Dobutamine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.76E-03 | 7 | P84022, Q13485, P42224, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Dobutamine | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Dobutamine | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Dobutamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Dobutamine | hsa04962 | Vasopressin-regulated water reabsorption | 2.18E-02 | 2 | P52566, P62491 | ARHGDIB, RAB11A | More | | Dobutamine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Dobutamine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Dobutamine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Dobutamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Dobutamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Dobutamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Dobutamine | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Dobutamine | hsa05031 | Amphetamine addiction | 8.84E-04 | 5 | Q13557, P22694, Q99941, P18848, Q13547 | CAMK2D, PRKACB, CREBL1, ATF4, HDAC1 | More | | Dobutamine | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | Dobutamine | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | Dobutamine | hsa05110 | Vibrio cholerae infection | 3.15E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | Dobutamine | hsa05130 | Pathogenic Escherichia coli infection | 7.39E-03 | 4 | Q14247, P56750, O00501, P25116 | CTTN, CLDN17, CLDN5, F2R | More | | Dobutamine | hsa05133 | Pertussis | 1.86E-03 | 3 | P09871, P0C0L4, Q02556 | C1S, C4A, IRF8 | More | | Dobutamine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Dobutamine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | | Dobutamine | hsa05145 | Toxoplasmosis | 3.45E-02 | 6 | P25963, Q13489, P42224, P09917, Q13751, P11142 | NFKBIA, BIRC3, STAT1, ALOX5, LAMB3, HSPA8 | More | | Dobutamine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | | Dobutamine | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Dobutamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Dobutamine | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Dobutamine | hsa05163 | Human cytomegalovirus infection | 1.62E-02 | 8 | P42338, P25963, P62873, P50151, P0DP23, P17252, P30101, P01568 | PIK3CB, NFKBIA, GNB1, GNG10, CALM1, PRKCA, PDIA3, IFNA21 | More | | Dobutamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.54E-04 | 13 | P01568, P42224, P25963, P42338, P40189, P62873, P62879, P50151, P19174, P16298, Q02750, P0DP23, P0CG47 | IFNA21, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNB2, GNG10, PLCG1, PPP3CB, MAP2K1, CALM1, UBB | More | | Dobutamine | hsa05168 | Herpes simplex virus 1 infection | 6.31E-03 | 13 | P25963, P01568, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212 | More | | Dobutamine | hsa05170 | Human immunodeficiency virus 1 infection | 1.54E-04 | 15 | P42338, Q02750, P62873, P62879, P50151, P16298, P0DP23, Q05397, P17252, P30101, P01568, P25963, P19174, P23528, P20333 | PIK3CB, MAP2K1, GNB1, GNB2, GNG10, PPP3CB, CALM1, PTK2, PRKCA, PDIA3, IFNA21, NFKBIA, PLCG1, CFL1, TNFRSF1B | More | | Dobutamine | hsa05171 | Coronavirus disease - COVID-19 | 3.30E-02 | 7 | P25963, P42224, P01568, P40189, P42338, P19174, P17252 | NFKBIA, STAT1, IFNA21, IL6ST, PIK3CB, PLCG1, PRKCA | More | | Dobutamine | hsa05200 | Pathways in cancer | 5.83E-06 | 29 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P84022, Q13485, Q13547, P10826, P14923, P30281, Q13489, P49767, P14921, P43657, P62873, P63218, P50151, Q14344, Q7LDG7, P78417, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, RARB, JUP, CCND3, BIRC3, VEGFC, ETS1, P2RY5, GNB1, GNG5, GNG10, GNA13, RASGRP2, GSTO1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.705 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.841 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.785 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.925 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P10826 | RARB | Retinoic acid receptor beta | 0.779 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14923 | JUP | Junction plakoglobin | -0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.747 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.871 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14921 | ETS1 | Protein C-ets-1 | 0.731 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.703 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.919 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.865 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.748 |
| Dobutamine | hsa05202 | Transcriptional misregulation in cancer | 6.64E-08 | 22 | Q12778, Q15532, Q13315, P41732, P14780, P27930, P14923, Q15744, Q16548, P11215, Q13489, Q13077, O15550, P08069, P35226, P05164, P12838, P08246, Q9C0K0, Q13547, P12980, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, IL1R2, JUP, CEBPE, BCL2A1, ITGAM, BIRC3, TRAF1, UTX, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, HDAC1, LYL1, GADD45A | More | | Dobutamine | hsa05203 | Viral carcinogenesis | 5.38E-04 | 8 | Q99941, P18848, P27348, Q13547, P61978, P58876, Q16778, O60814 | CREBL1, ATF4, YWHAQ, HDAC1, HNRPK, H2BC5, HIST2H2BE, H2BC12 | More | | Dobutamine | hsa05205 | Proteoglycans in cancer | 1.09E-02 | 6 | P14780, P01375, P08069, P23588, Q13635, P22694 | MMP9, TNF, IGF1R, EIF4B, PTCH1, PRKACB | More | | Dobutamine | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Dobutamine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Dobutamine | hsa05214 | Glioma | 4.14E-04 | 6 | P08069, P0DP23, P17252, P42338, P19174, O75293 | IGF1R, CALM1, PRKCA, PIK3CB, PLCG1, GADD45B | More | | Dobutamine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Dobutamine | hsa05222 | Small cell lung cancer | 1.10E-02 | 6 | P10826, P42338, Q13751, Q13489, P25963, O75293 | RARB, PIK3CB, LAMB3, BIRC3, NFKBIA, GADD45B | More | | Dobutamine | hsa05223 | Non-small cell lung cancer | 4.91E-03 | 5 | P17252, P42338, P19174, P10826, O75293 | PRKCA, PIK3CB, PLCG1, RARB, GADD45B | More | | Dobutamine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | | Dobutamine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Dobutamine | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | | Dobutamine | hsa05231 | Choline metabolism in cancer | 4.91E-03 | 5 | P42338, Q9Y259, P19174, P23743, P17252 | PIK3CB, CHKB, PLCG1, DGKA, PRKCA | More | | Dobutamine | hsa05321 | Inflammatory bowel disease | 1.30E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Dobutamine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | | Dobutamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Dobutamine | hsa05332 | Graft-versus-host disease | 8.27E-07 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Dobutamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Dobutamine | hsa05415 | Diabetic cardiomyopathy | 4.92E-03 | 5 | Q16718, O14521, Q16539, P49841, P11413 | NDUFA5, SDHD, MAPK14, GSK3B, G6PD | More | | |